FDA has approved Stivarga (regorafenib) oral tablets for the treatment of
patients with metastatic colorectal cancer who have been previously
treated with multiple other therapies. Stivarga inhibits multiple cellular pathways involved in tumor growth.
http://www.chemotherapyadvisor.com/stivarga-approved-for-metastatic-colorectal-cancer/article/261202/?DCMP=EMC-CTA_weekly&spMailingID=4866344&spUserID=MjMyNTIwMzY2OQS2&spJobID=54425681&spReportId=NTQ0MjU2ODES1
No comments:
Post a Comment